Permeable analogues of cGMP promote hepatic calcium inflow induced by the synergistic action of glucagon and vasopressin but inhibit that induced by vasopressin alone

Treatment of perfused rat liver with the nitric oxide-generating reagent molsidomine led to substantial increases in cGMP without itself affecting basal Ca2+ fluxes. Under these conditions the ability of glucagon plus vasopressin to induce Ca2+ influx was greatly enhanced. The permeable analogue of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical journal 1998-03, Vol.330 ( Pt 2) (2), p.877-880
Hauptverfasser:	Nguyen, L, Karjalainen, A, Milbourne, E A, Bygrave, F L
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Calcium - metabolism Cyclic GMP - analogs & derivatives Drug Synergism Glucagon - pharmacology Liver - drug effects Liver - metabolism Male Molsidomine - pharmacology Nitric Oxide - metabolism Perfusion Rats Rats, Wistar Vasoconstrictor Agents - pharmacology Vasodilator Agents - pharmacology Vasopressins - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	880
container_issue	2
container_start_page	877
container_title	Biochemical journal
container_volume	330 ( Pt 2)
creator	Nguyen, L Karjalainen, A Milbourne, E A Bygrave, F L
description	Treatment of perfused rat liver with the nitric oxide-generating reagent molsidomine led to substantial increases in cGMP without itself affecting basal Ca2+ fluxes. Under these conditions the ability of glucagon plus vasopressin to induce Ca2+ influx was greatly enhanced. The permeable analogue of cGMP (8-bromo-cGMP) enhanced glucagon plus vasopressin-induced Ca2+ influx to a similar extent as that with molsidomine. This suggests that the effect of the latter is attributable to the generation of cGMP which itself enhances the ability of the two hormones to induce synergistic Ca2+ influx. While 8-bromo-cGMP (or molsidomine) did not influence Ca2+ fluxes induced by glucagon, these agents strongly inhibited Ca2+ influx induced by vasopressin alone. These data show that while 8-bromo-cGMP has no effect on basal Ca2+ fluxes, it is able to modify the Ca2+ influx induced by glucagon and vasopressin action in hepatic tissue.
doi_str_mv	10.1042/bj3300877
format	Article
fullrecord	<record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1219219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9480904</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-5d00d48b1ea2720a6091496abb44395faa2fe911879880485ef5d779d61c3763</originalsourceid><addsrcrecordid>eNpVkcFq3DAQhkVJSLdpD32Agq49uB3ZWku6FEpo00BKcsjdjGTZq2BLRpJT9oXynNWSsGxg4B-Yf74Z-An5zOAbA15_149NAyCFeEc2jAuopKjlGdlA3fKqhZq9Jx9SegRgHDhckAvFJSjgG_J8b-NsUU-WoscpjKtNNAzUXP-9p0sMc8iW7uyC2RlqcDJunanzwxT-FelXY3uq9zTvLE17b-Po0sGJJrvgD6BxWg2OpUff0ydMYYk2JeepXnMh7Jx2uaxjPsWd-spT3n4k5wNOyX561Uvy8PvXw9Wf6vbu-ubq521lGgG52vYAPZeaWaxFDdiCYly1qDXnjdoOiPVgFWNSKCmBy60dtr0Qqm9ZAbTNJfnxgl1WPdveWJ8jTt0S3Yxx3wV03duJd7tuDE8dq5kqVQBfXwAmhpSiHY67DLpDVN0xquL9cnrs6HzNpvkPZG6Tbg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Permeable analogues of cGMP promote hepatic calcium inflow induced by the synergistic action of glucagon and vasopressin but inhibit that induced by vasopressin alone</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Nguyen, L ; Karjalainen, A ; Milbourne, E A ; Bygrave, F L</creator><creatorcontrib>Nguyen, L ; Karjalainen, A ; Milbourne, E A ; Bygrave, F L</creatorcontrib><description>Treatment of perfused rat liver with the nitric oxide-generating reagent molsidomine led to substantial increases in cGMP without itself affecting basal Ca2+ fluxes. Under these conditions the ability of glucagon plus vasopressin to induce Ca2+ influx was greatly enhanced. The permeable analogue of cGMP (8-bromo-cGMP) enhanced glucagon plus vasopressin-induced Ca2+ influx to a similar extent as that with molsidomine. This suggests that the effect of the latter is attributable to the generation of cGMP which itself enhances the ability of the two hormones to induce synergistic Ca2+ influx. While 8-bromo-cGMP (or molsidomine) did not influence Ca2+ fluxes induced by glucagon, these agents strongly inhibited Ca2+ influx induced by vasopressin alone. These data show that while 8-bromo-cGMP has no effect on basal Ca2+ fluxes, it is able to modify the Ca2+ influx induced by glucagon and vasopressin action in hepatic tissue.</description><identifier>ISSN: 0264-6021</identifier><identifier>EISSN: 1470-8728</identifier><identifier>DOI: 10.1042/bj3300877</identifier><identifier>PMID: 9480904</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Calcium - metabolism ; Cyclic GMP - analogs & derivatives ; Drug Synergism ; Glucagon - pharmacology ; Liver - drug effects ; Liver - metabolism ; Male ; Molsidomine - pharmacology ; Nitric Oxide - metabolism ; Perfusion ; Rats ; Rats, Wistar ; Vasoconstrictor Agents - pharmacology ; Vasodilator Agents - pharmacology ; Vasopressins - pharmacology</subject><ispartof>Biochemical journal, 1998-03, Vol.330 ( Pt 2) (2), p.877-880</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-5d00d48b1ea2720a6091496abb44395faa2fe911879880485ef5d779d61c3763</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1219219/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1219219/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9480904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, L</creatorcontrib><creatorcontrib>Karjalainen, A</creatorcontrib><creatorcontrib>Milbourne, E A</creatorcontrib><creatorcontrib>Bygrave, F L</creatorcontrib><title>Permeable analogues of cGMP promote hepatic calcium inflow induced by the synergistic action of glucagon and vasopressin but inhibit that induced by vasopressin alone</title><title>Biochemical journal</title><addtitle>Biochem J</addtitle><description>Treatment of perfused rat liver with the nitric oxide-generating reagent molsidomine led to substantial increases in cGMP without itself affecting basal Ca2+ fluxes. Under these conditions the ability of glucagon plus vasopressin to induce Ca2+ influx was greatly enhanced. The permeable analogue of cGMP (8-bromo-cGMP) enhanced glucagon plus vasopressin-induced Ca2+ influx to a similar extent as that with molsidomine. This suggests that the effect of the latter is attributable to the generation of cGMP which itself enhances the ability of the two hormones to induce synergistic Ca2+ influx. While 8-bromo-cGMP (or molsidomine) did not influence Ca2+ fluxes induced by glucagon, these agents strongly inhibited Ca2+ influx induced by vasopressin alone. These data show that while 8-bromo-cGMP has no effect on basal Ca2+ fluxes, it is able to modify the Ca2+ influx induced by glucagon and vasopressin action in hepatic tissue.</description><subject>Animals</subject><subject>Calcium - metabolism</subject><subject>Cyclic GMP - analogs & derivatives</subject><subject>Drug Synergism</subject><subject>Glucagon - pharmacology</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Male</subject><subject>Molsidomine - pharmacology</subject><subject>Nitric Oxide - metabolism</subject><subject>Perfusion</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Vasoconstrictor Agents - pharmacology</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vasopressins - pharmacology</subject><issn>0264-6021</issn><issn>1470-8728</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkcFq3DAQhkVJSLdpD32Agq49uB3ZWku6FEpo00BKcsjdjGTZq2BLRpJT9oXynNWSsGxg4B-Yf74Z-An5zOAbA15_149NAyCFeEc2jAuopKjlGdlA3fKqhZq9Jx9SegRgHDhckAvFJSjgG_J8b-NsUU-WoscpjKtNNAzUXP-9p0sMc8iW7uyC2RlqcDJunanzwxT-FelXY3uq9zTvLE17b-Po0sGJJrvgD6BxWg2OpUff0ydMYYk2JeepXnMh7Jx2uaxjPsWd-spT3n4k5wNOyX561Uvy8PvXw9Wf6vbu-ubq521lGgG52vYAPZeaWaxFDdiCYly1qDXnjdoOiPVgFWNSKCmBy60dtr0Qqm9ZAbTNJfnxgl1WPdveWJ8jTt0S3Yxx3wV03duJd7tuDE8dq5kqVQBfXwAmhpSiHY67DLpDVN0xquL9cnrs6HzNpvkPZG6Tbg</recordid><startdate>19980301</startdate><enddate>19980301</enddate><creator>Nguyen, L</creator><creator>Karjalainen, A</creator><creator>Milbourne, E A</creator><creator>Bygrave, F L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19980301</creationdate><title>Permeable analogues of cGMP promote hepatic calcium inflow induced by the synergistic action of glucagon and vasopressin but inhibit that induced by vasopressin alone</title><author>Nguyen, L ; Karjalainen, A ; Milbourne, E A ; Bygrave, F L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-5d00d48b1ea2720a6091496abb44395faa2fe911879880485ef5d779d61c3763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Calcium - metabolism</topic><topic>Cyclic GMP - analogs & derivatives</topic><topic>Drug Synergism</topic><topic>Glucagon - pharmacology</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Male</topic><topic>Molsidomine - pharmacology</topic><topic>Nitric Oxide - metabolism</topic><topic>Perfusion</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Vasoconstrictor Agents - pharmacology</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vasopressins - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, L</creatorcontrib><creatorcontrib>Karjalainen, A</creatorcontrib><creatorcontrib>Milbourne, E A</creatorcontrib><creatorcontrib>Bygrave, F L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochemical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, L</au><au>Karjalainen, A</au><au>Milbourne, E A</au><au>Bygrave, F L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Permeable analogues of cGMP promote hepatic calcium inflow induced by the synergistic action of glucagon and vasopressin but inhibit that induced by vasopressin alone</atitle><jtitle>Biochemical journal</jtitle><addtitle>Biochem J</addtitle><date>1998-03-01</date><risdate>1998</risdate><volume>330 ( Pt 2)</volume><issue>2</issue><spage>877</spage><epage>880</epage><pages>877-880</pages><issn>0264-6021</issn><eissn>1470-8728</eissn><abstract>Treatment of perfused rat liver with the nitric oxide-generating reagent molsidomine led to substantial increases in cGMP without itself affecting basal Ca2+ fluxes. Under these conditions the ability of glucagon plus vasopressin to induce Ca2+ influx was greatly enhanced. The permeable analogue of cGMP (8-bromo-cGMP) enhanced glucagon plus vasopressin-induced Ca2+ influx to a similar extent as that with molsidomine. This suggests that the effect of the latter is attributable to the generation of cGMP which itself enhances the ability of the two hormones to induce synergistic Ca2+ influx. While 8-bromo-cGMP (or molsidomine) did not influence Ca2+ fluxes induced by glucagon, these agents strongly inhibited Ca2+ influx induced by vasopressin alone. These data show that while 8-bromo-cGMP has no effect on basal Ca2+ fluxes, it is able to modify the Ca2+ influx induced by glucagon and vasopressin action in hepatic tissue.</abstract><cop>England</cop><pmid>9480904</pmid><doi>10.1042/bj3300877</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0264-6021
ispartof	Biochemical journal, 1998-03, Vol.330 ( Pt 2) (2), p.877-880
issn	0264-6021 1470-8728
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1219219
source	MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects	Animals Calcium - metabolism Cyclic GMP - analogs & derivatives Drug Synergism Glucagon - pharmacology Liver - drug effects Liver - metabolism Male Molsidomine - pharmacology Nitric Oxide - metabolism Perfusion Rats Rats, Wistar Vasoconstrictor Agents - pharmacology Vasodilator Agents - pharmacology Vasopressins - pharmacology
title	Permeable analogues of cGMP promote hepatic calcium inflow induced by the synergistic action of glucagon and vasopressin but inhibit that induced by vasopressin alone
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A49%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Permeable%20analogues%20of%20cGMP%20promote%20hepatic%20calcium%20inflow%20induced%20by%20the%20synergistic%20action%20of%20glucagon%20and%20vasopressin%20but%20inhibit%20that%20induced%20by%20vasopressin%20alone&rft.jtitle=Biochemical%20journal&rft.au=Nguyen,%20L&rft.date=1998-03-01&rft.volume=330%20(%20Pt%202)&rft.issue=2&rft.spage=877&rft.epage=880&rft.pages=877-880&rft.issn=0264-6021&rft.eissn=1470-8728&rft_id=info:doi/10.1042/bj3300877&rft_dat=%3Cpubmed_cross%3E9480904%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9480904&rfr_iscdi=true